GeneOS is a privacy-preserving data monetization protocol for Protected Health Information, i.e. genetic, activity, and medical data.
By combining private AI and Blockchain technology, we enable a privacy-guaranteed data rental market. Your biological data can turn into an income-generating digital asset, like a rental property.
Putting Your Data
In Your Hands
While all data have privacy concerns, biological data is arguably the most intimate type of data that we own.
The new data economy is worth more than $300 billion and rapidly growing. With new private AI technologies, you can still participate in the data economy without exposing your data to anybody.
- Activity Data
- Sleep Data
- DNA Sequencing
- Medical Records
- Lab Results
Right now you're getting
A Raw Deal
Your data is the oil that powers the engines of the new AI economy. Today, your biological data is scattered among different data custodians such as hospitals, labs, fitness trackers, who have complete control over it.
This data is then sold to interested parties for profit with the only guarantee being a weak promise that your data would be anonymized. As a result, not only is your privacy threatened, you also have no participation in the economic value generated by your data.
GeneOS believes you have a sovereign right to benefit both financially and medically from the data you generate.
With GeneOS, you can see what your data would be used for, get direct payment for it, all the while maintaining complete privacy. This is our vision for the future.
A Fair Model
Benefit the World
With enough health data, we can make major breakthroughs in medical science. But until now, life-saving data could not be shared fairly.
Our Genome Equity Model (GEM) turns your data into a digital hard asset on the blockchain. Combined with private AI technology, we will now be able to:
- Find cures to deadly diseases
- Preserve individual data soverignty and privacy
- Enable Biological Dividends™
Sign Up For Our
GeneOS Beta Protocol will be launching Q1 2020.
Sign up for our newsletter for early access and updates on our development.